Geoffrey T. Yarranton

Biography

Dr. Yarranton is on the Board of Managers and is the acting CEO of NGPD. He provides strategic and operational leadership on product development. Dr. Yarranton is a senior executive in the biopharmaceutical industry with over 35 years of experience. He has been involved in the development of three approved therapeutic antibody products: Mylotarg®, Bexxar® and Cimzia®. He has held senior research and development positions in UK and US biotech companies. In 2004 he lead the merger of Celscia Therapeutics with KaloBios to form KaloBios Pharmaceuticals, and as CEO he raised a $21M Series B financing. Subsequently he became Chief Scientific Officer at KaloBios Pharmaceuticals and guided the development of antibody humaneering® technology and three antibody clinical candidates (KB001-A, KB003 and KB004). He is an inventor on over 20 US patents.  In 2013, he was part of the team that secured a successful NASDAQ listing for KaloBios Pharmaceuticals. 

Research Interest

 Pharmaceutical science